Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy

ISBN-13: 9783319675756 / Angielski / Twarda / 2018 / 264 str.

Pawel Kalinski

Opis

The tumor microenvironment has become a very important and hot topic in cancer research within the past few years. The tumor microenvironment is defined as the normal cells, molecules, and blood vessels that surround and feed a tumor cell. As many scientists have realized, studying the tumor microenvironment has become critical to moving the field forward, since there are many players in a tumor's localized and surrounding area, which can significantly change cancer cell behavior. There is a dual relationship wherein the tumor can change its microenvironment and the microenvironment can affect how a tumor grows and spreads. Tumor Microenvironment in Cancer Progression and Cancer Therapy aims to shed light on the mechanisms, factors, and mediators that are involved in the cancer cell environment. Recent studies have demonstrated that in addition to promoting tumor progression and protecting tumor cells from the spontaneous immune-mediated rejection and different forms of cancer therapeutics, tumor microenvironment can also be a target and mediator of both standard and newly-emerging forms of cancer therapeutics. Thus, the dual role of the tumor microenvironment is the integral focus of the volume. The volume highlights the bi-directional interactions between tumor cells and non-malignant tumor component during tumor progression and treatment. It also focuses on the three groups of the reactive tumor component: stromal cells, blood vessels and the infiltrating immune cells. These three groups are discussed under the lens of their role in promoting tumor growth, shielding the tumor from rejection and from standard forms of cancer therapies. They are emerging as targets and mediators of standard and new forms of potential therapy.

Spis treści

Part 1. Interplay Between Tumor Cells, Stroma and Inflammatory Infiltrate in Regulating Tumor Micro-Environment.- Tumor Immuno-Environment in Cancer Progression and Therapy.- Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.- Regulation of CTL Infiltration Within the Tumor Microenvironment.- The Role of Tumor Microenvironment in Cancer Immunotherapy.- Part 2. Mediators of Tumor Microenvironment.- Immunogenic and Non-Immunogenic Cell Death in the Tumor Microenvironment.- Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression.- Chemo-immunotherapy: Impact of Indoleamine 2,3-dioxygenase in Defining Immunogenic versus Tolerogenic Cell Death in the Tumor Microenvironment.- Targeting Myeloid-Derived Suppressor Cells in Cancer.- Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune Suppression.- Part 3. Emerging Targets and Technologies of Modulation of Tumor Microenvironment.- Tumor Microenvironment in Cancer Progression and Therapy.- The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma.- Oncolytic Virotherapy and the Tumor Microenvironment.- The Impact of Housing Temperature Induced Chronic Stress on Preclinical Mouse Tumor Models and Therapeutic Responses: An Important Role for the Nervous Role for the Nervous System.- (Immuno)therapeutic Targeting of Tumor-Associated Blood Vessels.- Adaptive Resistance to Cancer Immunotherapy.- Imaging the Tumor Microenvironment.

O autorze

Pawel Kalinski, M.D., Ph.D., is the Vice Chair for Translational Research and Professor of Oncology in the Department of Medicine at Roswell Park Cancer Institute (RPCI) in Buffalo, NY. He is also the Director of Cancer Vaccine and Dendritic Cell Therapies in the Center for Immunotherapy, and a Co-Leader of the Tumor Immunology & Immunotherapy Program of RPCI. Dr. Kalinski is a member of the Society for Immunotherapy of Cancer (SITC), American Association of Immunologists (AAI), American Association for Cancer Research (AACR) and the American Society of Clinical Investigation (ASCI) and an editorial board member of several journals in the area of cancer immunology and immunotherapy. He has been the recipient of multiple grants from the National Cancer Institute in recent years. Dr. Kalinski has published over 130 papers in the areas of immunology and cancer research and has been cited over 5,500 times.